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K E Y W O R D S
clomiphene,	metformin,	ovulation	induction,	polycystic	ovary	syndrome
1  | INTRODUCTION
Polycystic	ovary	syndrome	 (PCOS)	 is	an	ovulatory	disorder	 that	 is	char-
acterized	 by	 hyperandrogenism,	 infertility,	 and	 anovulation	 that	 is	 seen	
in	 6%-	10%	 of	women	 of	 reproductive	 age.	 Insulin	 resistance,	 diabetes,	
and	 hypertension	 are	 involved	 in	 the	 pathophysiology	 of	 PCOS,1 and 
metformin,	an	anti-	diabetic	agent,	has	been	reported	to	be	useful	for	induc-
ing	ovulation	in	patients	with	PCOS.	The	Japan	Society	of	Obstetrics	and	
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combination	therapy	in	clomiphene-	resistant	patients	was	more	effective	






2  | MATERIALS AND METHODS
2.1 | Participants
This	study	was	a	retrospective	study	of	metformin	treatments	for	Japanese	
patients	with	PCOS	 for	ovulation	 induction,	using	a	questionnaire	 in	18	
facilities.	 The	 questionnaire	 was	 sent	 to	 Okayama	 University,	 Kurashiki	
Central	 Hospital,	 Kurashiki	 Medical	 Center,	 Okayama	 Couple’s	 Clinic,	
Okayama	 Aiiku	 Clinic,	 Yamaguchi	 University,	 Yamaguchi	 Prefectural	
Grand	Medical	Center,	Saiseikai	Shimonoseki	General	Hospital,	Shimane	
University,	 Shimane	 Prefectural	 Central	 Hospital,	 Matsue	 City	 Hospital,	
Hiroshima	 Prefectural	 Hospital,	 Kinutani	 Women’s	 Clinic,	 Tottori	
University,	 Kochi	University,	 Tokushima	University,	 Sanno	Hospital,	 and	
Mimuro	Women’s	Clinic.	The	metformin	treatment	was	classified	into	four	
types:	(1)	clomiphene–metformin	combination	treatment	for	clomiphene-	
resistant	 patients;	 (2)	 clomiphene–metformin	 combination	 treatment	 for	
clomiphene-	sensitive	 patients;	 (3)	 clomiphene–metformin	 combination	
treatment	for	naïve	patients,	who	have	no	treatment	history	of	clomiphene;	







2.2.1 | Clomiphene–metformin combination for the 
clomiphene- resistant patients
A	total	of	80	clomiphene-	resistant	patients	with	PCOS	with	221	cy-
cles	 underwent	 clomiphene–metformin	 combination	 treatment.	 The	
ovulation	rates	per	cycle	and	per	case,	pregnancy	rates	per	cycle	and	
per	case,	and	the	single	follicular	development	rate	were	analyzed.	In	
addition,	 subanalyses	were	 carried	 out	 according	 to	 the	 Body	Mass	
Index	 (BMI)	 (n=70),	 homeostasis	 model	 assessment-	insulin	 resist-
ance	 (HOMA-	IR)	 (n=39),	 and	 fasting	 insulin	 (n=39)	 levels.	 Seventy	
patients	 who	 had	 BMI	 data	 were	 divided	 into	 four	 subgroups:	 lean	
(BMI<18.5	kg/m2)	(n=9),	normal	(BMI=18.5-	25.0	kg/m2)	(n=30),	over-
weight	 (BMI=25.0-	30.0	kg/m2)	 (n=15),	 and	 obese	 (BMI>30.0	kg/m2)	
(n=16).	 Thirty-	nine	 patients	 who	 had	 HOMA-	IR	 data	 were	 divided	
into	 four	subgroups:	HOMA-	IR<0.8	 (n=6),	HOMA-	IR=0.8-	1.6	 (n=10),	
HOMA-	IR=1.6-	2.5	 (n=6),	 and	 HOMA-	IR>2.5	 (n=17).	 Thirty-	nine	 pa-
tients	who	had	fasting	insulin	data	were	divided	into	two	subgroups:	
<15	μU/mL	fasting	insulin	(n=29)	and	≥15	μU/mL	fasting	insulin	(n=10).
2.2.2 | Clomiphene–metformin combination for the 
clomiphene- sensitive patients
The	clomiphene–metformin	combination	treatment	was	given	to	57	
patients	who	 failed	 at	 least	 three	 cycles	 of	 clomiphene	 therapy	 for	
ovulation	induction.	In	total,	205	cycles	were	analyzed	as	the	clomi-










2.2.3 | Clomiphene–metformin combination for the 
naïve patients
“Naïve”	patients	were	defined	as	having	no	treatment	history	of	clo-





















2.5 | Dose of metformin, definition of clomiphene 
resistance, and ovulation rate per case
The	usage	of	metformin	and	its	duration	were	determined	by	each	
facility.	 Clomiphene	 resistance	was	 defined	 as	 no	 ovulation	with	
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100	mg	of	 clomiphene,	 or	 at	 least	 two	 cycles.	 The	occurrence	of	
ovulation	per	case	with	multiple	treatment	cycles	was	determined	






the	chi	 square	 test.	 In	all	 the	analyses,	P<.05	was	considered	 to	be	
significant.
3  | RESULTS
3.1 | Clomiphene–metformin combination treatment 
for the clomiphene- resistant patients
The	mean	 clomiphene	dose	was	126.3±33.1	mg/d	 (mean	±	stand-
ard	 deviation	 [SD]).	 The	 clomiphene	 doses	 were	 150	mg/day	
(47.5%,	 105/221)	 and	 100	mg/d	 (43.8%,	 97/221),	 both	 of	 which	
accounted	 for	 90.6%	 of	 all	 the	 treated	 cycles	 (Table	1,	 Figure	1).	
The	mean	metformin	dose	was	690.1±163.9	mg/d.	The	metformin	
doses	 were	 predominantly	 750	mg/day	 (74.9%,	 164/219)	 in	 all	
the	 cycles.	Most	of	 the	 cycles	 for	 the	metformin-	treated	patients	
(85.8%,	169/197)	were	treated	with	metformin	continuous	admin-
istration	and	the	others	 (14.2%,	28/197)	were	treated	with	short-	




Figure	2).	 The	 pregnancy	 rate	was	 9.9%	per	 cycle	 and	 21.9%	per	
case.	 In	 the	 BMI	 subanalysis,	 the	 pregnancy	 rate	 was	 higher	 in	
the	obese	group	than	in	the	other	three	groups	in	both	cycles	and	
cases	(Figure	3).	The	ovulation	rates	and	pregnancy	rates	were	sig-








Characteristic C+M for CR C+M for CS C+M for naïve M
Cycle 221 205 12 42
Case 80 57 7 18
Age	(years) 29.6±4.0	(21-	38) 31.0±4.5	(22-	43) 29.9±3.7	(26-	36) 33.2±4.7	(25-	40)
Height	(cm) 157.9±5.9	(145-	178) 156.1±4.8	(148-	168) 157.7±5.3	(152-	166) 158.8±5.0	(150-	172)
Weight	(kg) 62.9±16.6	(40-	105.6) 57.5±13.5	(42-	93) 59.6±17.8	(44-	94.7) 70.5±15.5	(53-	114)
Body	mass	index	(kg/m2) 25.2±6.5	(17.3-	45.0) 23.6±5.4	(17.2-	38.7) 23.7±5.8	(18.8-	34.4) 28.0±6.1	(20.9-	46.3)
Rate	of	lean	and	normal	cases	(%) 55.7 72.2 57.1 38.9
(39/70) (39/54) (4/7) (7/18)
Rate	of	overweight	and	obese	cases	(%) 44.3 27.8 42.9 61.1
(31/70) (15/54) (3/7) (11/18)
Age	of	menarche	(years) 12.5±1.6	(10-	18) 12.4±1.4	(10-	15) 12.4±1.1	(11-	14) 12±1.4	(10-	15)
Number	of	gravida 0.6±0.8	(0-	3) 0.8±1.2	(0-	5) 0.0 1.3±1.7	(0-	5)
Number	of	para 0.4±0.6	(0-	2) 0.3±0.5	(0-	2) 0.0 0.2±0.4	(0-	1)
Fasting	glucose	(mg/dL) 92.6±10.4	(70-	127) 97.3±16.6	(82-	176) 89.3±6.4	(82-	93) 97.0±17.1	(72-	145)
Fasting	insulin	(μu/mL) 16.0±32.6	(0.3-	197.8) 10.5±7.1	(2.2-	27.3) 8.2±13.5	(0.34-	23.8) 16.1±23.8	(0.3-	99.3)
HOMA-	IR 4.0±9.0	(0.06-	55.7) 2.7±2.2	(0.5-	8.8) 0.7±0.1	(0.7-	0.8) 4.6±8.7	(0.1-	35.6)
LH	(mIU/mL) 9.0±4.7	(1.6-	25.9) 10.8±8.7	(0.4-	42.9) 13.3±9.1	(4.0-	28.7) 6.5±4.0	(1.8-	12.4)
FSH	(mIU/mL) 5.9±1.6	(2.4-	13.4) 5.8±2.0	(2.0-	12.1) 5.2±0.9	(4.1-	6.4) 7.6±6.7	(3.9-	32.5)
LH/FSH	ratio 1.6±0.9	(0.3-	5.0) 2.2±2.7	(0.1-	17.2) 2.6±1.8	(1.0-	4.9) 1.0±0.7	(0.3-	3.0)
PRL	(ng/mL) 13.8±7.9	(3.3-	44.3) 16.5±8.5	(2.7-	41.3) 11.0±2.8	(8.7-	15.3) 11.6±6.8	(4.2-	34.4)
Testosterone	(ng/mL) 0.6±0.3	(0.2-	1.3) 1.0±1.6	(0.1-	8.0) 0.6±0.3	(0.4-	1.1) 0.9±0.7	(0.1-	3.1)
DHEA-	S	(ng/mL) 1535±546	(494-	2500) 1717±533	(1030-	2510) 2350±710	(1140-	3600) 1990
E2	(pg/mL) 63.2±58.8	(9.3-	325.0) 85.2±66.5	(3.1-	185.0) 57.0±32.7	(23.0-	101.0) 40.7±10.4	(25.0-	53.4)
C+M	for	CR,	clomiphene–metformin	combination	treatment	for	the	clomiphene-	resistant	patients;	C+M	for	CS,	clomiphene–metformin	combination	treat-
ment	for	the	clomiphene-	sensitive	patients;	C+M	for	naïve,	clomiphene–metformin	combination	treatment	for	the	naïve	patients;	DHEA-	S,	dehydroepian-
drosterone	 sulfate;	 E2,	 estradiol;	 FSH,	 follicle-	stimulating	 hormone;	 HOMA-	IR,	 homeostasis	 model	 assessment	 of	 insulin	 resistance;	 LH,	 luteinizing	
hormone;	M,	metformin	monotherapy;	PRL,	prolactin.















































































126.3±33.1 dose (mg/day) 690.1±163.9 dose (mg/day)
98.5±41.6 dose (mg/day) 614.4±124.9 dose (mg/day)







Characteristic C+M for CR C+M for CS C+M for naïve M
Per cycle
Dose	of	clomiphene	(mg/d) 126.3±33.1	(50–200) 98.5±41.6	(50–200) 91.7±46.9	(50–150) –
Dose	of	metformin	(mg/d) 690.1±163.9	(250–1500) 614.4±124.9	(500–750) 520.8±198.2	(250–750) 577.4±151.1	(250–750)
Ovulation	rate	(%) 65.1	(138/212) 91	(181/199) 83.3	(10/12) 75	(27/36)
Number	of	developing	follicles 1.3±0.6	(1-	4) 1.4±1.2	(1-	10) 1.6±1.0	(1-	3) 1.0±0.2	(1-	2)
Rate	of	single	follicular	
development	(%)
81.1	(107/132) 76.1	(140/184) 71.4	(5/7) 95.5	(21/22)
Number	of	days	for	follicular	
development
20.0±6.3	(10–43) 17.3±4.3	(8–39) 20±3.7	(14–25) 18.3±5.3	(11–28)
Pregnancy	(%) 9.9	(21/212) 16.7	(33/198) 62.5	(5/8) 15.6	(5/32)
Abortion	rate	(%) 19	(4/21) 15.6	(5/32) 20	(1/5) 40	(2/5)
Stillbirth	rate	(%) 5.9	(1/17) 0	(0/21) – 0	(0/1)
Multiple	pregnancy	rate	(%) 0	(0/16) 0	(0/23) 0	(0/2) 0	(0/5)
Incidence	of	OHSS	(%) 0	(0/53) 0	(0/59) 0	(0/3) 0	(0/6)











Ovulation	rate	(%) 69.9	(51/73) 94.3	(50/53) 85.7	(6/7) 60.0	(9/15)
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HOMA-	IR<0.8	group,	9.1%	in	the	HOMA-	IR=0.8-	1.6	group,	10.0%	
in	 the	HOMA-	IR=1.6-	2.5	 group,	 and	 16.1%	 in	 the	HOMA-	IR≥2.5	
group;	 there	 was	 no	 significant	 difference	 among	 the	 groups,	 al-
though	the	high	HOMA-	IR	group	tended	to	have	a	higher	pregnancy	
rate	than	the	others.
3.2 | Clomiphene–metformin combination treatment 
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3.3 | Clomiphene–metformin combination treatment 
for the naïve patients
The	 mean	 clomiphene	 dose	 was	 91.7±46.9	mg/d.	 The	 clomiphene	
doses	 were	 50	mg/d	 (50.0%,	 6/12)	 and	 150	mg/d	 (33.3%,	 4/12),	
both	of	which	accounted	for	83.3%	of	all	the	treated	cycles	(10/12)	
(Table	1,	Figure	1).	The	mean	metformin	dose	was	520.8±198.2	mg/d.	
The	metformin	 doses	were	 500	mg/d	 (41.7%,	 5/12)	 and	 750	mg/d	
(33.3%,	4/12).	Most	of	the	cycles	(62.5%,	5/8)	were	treated	with	met-





rate	 seemed	high,	 the	usefulness	of	 the	 treatment	was	not	evident	
because	of	the	small	number	of	cases.
3.4 | Metformin monotherapy

























one	case	of	premature	 rupture	of	 the	membranes,	 and	one	case	of	
placenta	previa	(19.3%,	6/31)	(Table	4).
3.6 | Incidence of side- effects
Side-	effects	 of	 the	 metformin	 treatments	 were	 observed	 in	 3.6%	
(17/472)	of	the	patients:	diarrhea,	vomiting,	and	stomach	ache	were	
classified	as	digestive	system	dysfunction	(Table	5).	There	was	no	sig-





































4291   28 8 93 41    29 8 
 Ovulation rate 
Number of cycles      Number of cases
 Pregnancy rate 
  Number of cycles    Number of cases      
%
Fasting insulin 





demonstrated	 that	 metformin	 had	 a	 higher	 ovulation	 induction	
effect	 than	 did	 the	 placebo	 in	 PCOS	 (odds	 ratio	 [OR]=3.88,	 95%	




example,	 multiple	 pregnancies	 have	 not	 occurred	with	 metformin	
therapy	 in	 Italy,10	whereas	 they	have	occurred	 in	6.0%	of	patients	
in	 the	 USA	 in	 a	 randomized,	 controlled	 trial11	 during	 clomiphene	
therapy.	The	metformin	treatment	was	effective	 in	 inducing	ovula-
tion	or	recovering	the	normal	menstrual	cycle	in	the	lean	or	normal	
BMI	patients	with	PCOS.12–20	 Furthermore,	 some	 reports	have	 in-
dicated	 that	 non-	obese	 (BMI<30	kg/m2)	 patients	with	 PCOS	were	
more	 likely	 to	 respond	 to	 metformin	 than	 obese	 (BMI≥30	kg/m2)	
patients	with	 PCOS	 due	 to	 decreased	 sex	 steroids	 and	 increased	
ovulation	 rates.12,14	 From	 the	 present	 study,	 the	 metformin	 dose	
for	PCOS	in	Japan	was	750	mg/d.	However,	1500-	2500	mg/d	is	fre-











therapy	 for	 the	ovulation	 rate	 (OR=6.82,	95%	CI=3.59-	12.96),22	preg-











(no ovulation) First choice Habitual abortion
No pregnancy by 
clomiphene in the 
ovulated cycle High HOMA- IR
Number	of	cycles 21 10 7 1 3
Number	of	cases 6 5 4 1 2
Per cycle
Ovulation	rate	(%) 60	(12/20) 83.3	(5/6) 100	(7/7) – 66.7	(2/3)
Number	of	developing	follicles† 1.0±0.0 1.0±0.0 1.0±0.0 2 –
(n=13) (n=2) (n=4) (n=1)
Number	of	days	for	follicular	
developmenta
20.2±5.0	(14–28) 21.4±2.5	(19–25) 14.3±3.7	(12–20) 11 11.5±0.7	(11–12)
Pregnancy	rate	(%) 0	(0/14) 14.3	(1/7) 42.9	(3/7) (0/1) 33.3	(1/3)
Abortion	rate	(%) – 0	(0/1) 66.7	(2/3) – 0	(0/1)
Per case
Ovulation	rate	(%) 40	(2/5) 100	(3/3) 100	(4/4) – 50	(1/2)









































formin	 combination	 treatment	 than	with	 clomiphene	monotherapy	 in	
clomiphene-	resistant	patients	(OR=4.86,	95%	CI=2.43-	9.74).9	However,	
the	factors	that	are	related	to	the	response	to	clomiphene–metformin	
combination	 treatment	 have	 not	yet	 been	 established.	 In	 the	 present	
study,	 the	obese	group	 (BMI>30	kg/m2)	 had	 significantly	higher	preg-







<15	μU/mL.	The	BMI	and	 fasting	 insulin	 are	not	perfect	 as	 factors	 to	
predict	the	response	to	treatment.	 In	addition,	the	HOMA-	IR	was	less	
useful	in	predicting	the	responders.
For	 the	 pregnancy	 outcomes,	 spontaneous	 abortion	 in	 the	 first	
trimester	 occurred	 in	 20%	 (12/60)	 and	 17.5%	 (10/57)	 of	 the	 pa-
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TABLE  5 Side-	effects	of	the	metformin	treatment
Treatment Drug Side- effect (%) Side- effects
1.	C+M	for	CR Clomiphene–metformin 5.5 Diarrhea	(5),	vomiting	(2),	nausea	(1),	bad	mood	(1),	liver	dysfunction	(1),	
heartburn	(1),	eyestrain	(1),	and	uncertain	(3)a(12/217)
2.	C+M	for	CS Clomiphene–metformin 2 Diarrhea	(2),	nausea	(1),	and	stomach	ache	(1)
(4/202)
3.	C+M	for	naïve Clomiphene–metformin 0.0 –
(0/12)
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